{"title_page": "Eldelumab", "text_new": "{{Drugbox\n| type = mab\n| image = \n| alt = \n| mab_type =mab <!-- mab, Fab, F(ab')2, Fab', scFv, di-scFv, 3funct, clFab, BiTE --> \n| source = u<!-- a, e, i, o, u, xi/a, zu/a, xizu/a, axo, ... -->\n| target = CXCL10/IP-10<!-- antigen, not the code number of the monoclonal antibody! -->\n<!-- \"IgG1 kappa\". Don't know where to enter this. pls check drugbox documentation on mab. -->\n| tradename = \n| Drugs.com = \n| MedlinePlus = \n| pregnancy_AU = \n| pregnancy_US = \n| pregnancy_category=  \n| legal_AU = \n| legal_CA = \n| legal_UK = \n| legal_US = \n| legal_status = \n| routes_of_administration = \n| bioavailability = \n| protein_bound = \n| metabolism = \n| elimination_half-life = \n| excretion = \n| CAS_number = 946414-98-8\n| UNII_Ref = {{fdacite|correct|FDA}}\n| UNII = 15O91A27I5\n| ATC_prefix = none\n| ATC_suffix = \n| PubChem = \n| DrugBank = \n| KEGG = D10404\n| ChemSpiderID = none\n| C=6502 | H=10024 | N=1736 | O=2026 | S=48\n| molecular_weight = 146.5 kg/mol\n| drug_name=\n| caption=\n| licence_EU=\n| licence_US=}}\n\n'''Eldelumab''' (alternative identifier BMS-936557<ref name = \"Sandborn_2016\">{{cite journal | vauthors = Sandborn WJ, Colombel JF, Ghosh S, Sands BE, Dryden G, H\u00e9buterne X, Leong RW, Bressler B, Ullman T, Lakatos PL, Reinisch W, Xu LA, Luo A | display-authors = 6 | title = Eldelumab [Anti-IP-10] Induction Therapy for Ulcerative Colitis: A Randomised, Placebo-Controlled, Phase 2b Study | journal = Journal of Crohn's & Colitis | volume = 10 | issue = 4 | pages = 418\u201328 | date = April 2016 | pmid = 26721935 | pmc = 4946756 | doi = 10.1093/ecco-jcc/jjv224 }}</ref>) is a fully human [[monoclonal antibody]] (type IgG1 kappa)<ref name=\":0\">{{Cite web|url=http://www.creativebiolabs.net/Anti-CXCL10-Therapeutic-Antibody-eldelumab-13658.htm|title=Anti-CXCL10 Therapeutic Antibody (eldelumab) - Creative Biolabs|website=www.creativebiolabs.net|access-date=2017-03-24}}</ref> that targets chemokine (C-X-C motif) ligand 10 ([[CXCL10]])/Interferon-\u03b3-inducible protein-10 (IP-10)<ref name=\":0\" /><ref name = \"Sandborn_2016\" /> designed for the treatment of [[Crohn's disease]] and [[ulcerative colitis]].<ref>[http://www.ama-assn.org/resources/doc/usan/eldelumab.pdf Statement On A Nonproprietary Name Adopted By The USAN Council - Eldelumab], ''[[American Medical Association]]''.</ref> \n\nThis drug was developed by [[Bristol-Myers Squibb]] and Medarex.<ref>{{Cite web |url= http://adisinsight.springer.com/drugs/800018487 |title=Eldelumab | work = AdisInsight | publisher = Springer Nature Switzerland AG }}</ref>\n\n== References ==\n{{reflist}}\n\n{{Monoclonals for immune system}}\n{{Chemokine receptor modulators}}\n\n[[Category:Bristol-Myers Squibb]]\n[[Category:Monoclonal antibodies]]\n\n{{monoclonal-antibody-stub}}\n", "text_old": "{{Drugbox\n| type = mab\n| image = \n| alt = \n| mab_type =mab <!-- mab, Fab, F(ab')2, Fab', scFv, di-scFv, 3funct, clFab, BiTE --> \n| source = u<!-- a, e, i, o, u, xi/a, zu/a, xizu/a, axo, ... -->\n| target = CXCL10/IP-10<!-- antigen, not the code number of the monoclonal antibody! -->\n<!-- \"IgG1 kappa\". Don't know where to enter this. pls check drugbox documentation on mab. -->\n| tradename = \n| Drugs.com = \n| MedlinePlus = \n| pregnancy_AU = \n| pregnancy_US = \n| pregnancy_category=  \n| legal_AU = \n| legal_CA = \n| legal_UK = \n| legal_US = \n| legal_status = \n| routes_of_administration = \n| bioavailability = \n| protein_bound = \n| metabolism = \n| elimination_half-life = \n| excretion = \n| CAS_number = 946414-98-8\n| ATC_prefix = none\n| ATC_suffix = \n| PubChem = \n| DrugBank = \n| KEGG = D10404\n| ChemSpiderID = none\n| C=6502 | H=10024 | N=1736 | O=2026 | S=48\n| molecular_weight = 146.5 kg/mol\n| drug_name=\n| caption=\n| licence_EU=\n| licence_US=}}\n\n'''Eldelumab''' (alternative identifier BMS-936557<ref name = \"Sandborn_2016\">{{cite journal | vauthors = Sandborn WJ, Colombel JF, Ghosh S, Sands BE, Dryden G, H\u00e9buterne X, Leong RW, Bressler B, Ullman T, Lakatos PL, Reinisch W, Xu LA, Luo A | display-authors = 6 | title = Eldelumab [Anti-IP-10] Induction Therapy for Ulcerative Colitis: A Randomised, Placebo-Controlled, Phase 2b Study | journal = Journal of Crohn's & Colitis | volume = 10 | issue = 4 | pages = 418\u201328 | date = April 2016 | pmid = 26721935 | pmc = 4946756 | doi = 10.1093/ecco-jcc/jjv224 }}</ref>) is a fully human [[monoclonal antibody]] (type IgG1 kappa)<ref name=\":0\">{{Cite web|url=http://www.creativebiolabs.net/Anti-CXCL10-Therapeutic-Antibody-eldelumab-13658.htm|title=Anti-CXCL10 Therapeutic Antibody (eldelumab) - Creative Biolabs|website=www.creativebiolabs.net|access-date=2017-03-24}}</ref> that targets chemokine (C-X-C motif) ligand 10 ([[CXCL10]])/Interferon-\u03b3-inducible protein-10 (IP-10)<ref name=\":0\" /><ref name = \"Sandborn_2016\" /> designed for the treatment of [[Crohn's disease]] and [[ulcerative colitis]].<ref>[http://www.ama-assn.org/resources/doc/usan/eldelumab.pdf Statement On A Nonproprietary Name Adopted By The USAN Council - Eldelumab], ''[[American Medical Association]]''.</ref> \n\nThis drug was developed by [[Bristol-Myers Squibb]] and Medarex.<ref>{{Cite web |url= http://adisinsight.springer.com/drugs/800018487 |title=Eldelumab | work = AdisInsight | publisher = Springer Nature Switzerland AG }}</ref>\n\n== References ==\n{{reflist}}\n\n{{Monoclonals for immune system}}\n{{Chemokine receptor modulators}}\n\n[[Category:Bristol-Myers Squibb]]\n[[Category:Monoclonal antibodies]]\n\n{{monoclonal-antibody-stub}}\n", "name_user": "Fswitzer4", "label": "safe", "comment": "added FDA UNII to drug box", "url_page": "//en.wikipedia.org/wiki/Eldelumab"}
